Skip to content

Comparison of clinical efficacy and safety of different concentrations of etomidate-propofol mixture for painless gastroscopy in adult patients

Comparison of clinical efficacy and safety of different concentrations of etomidate-propofol mixture for painless gastroscopy in adult patients

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035822
Enrollment
Unknown
Registered
2020-08-18
Start date
2020-08-18
Completion date
Unknown
Last updated
2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedative drug-related complications

Interventions

Group 2:1:2 Volume ratio etomidate-propofol mixture
Group 3:1:3 Volume ratio etomidate-propofol mixture

Sponsors

Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Subjects aged 18-80 years; 2. The subject of sex is not limited; 3. Subjects with BMI of 18-30 kg / m2; 4. ASA I-III objects.

Exclusion criteria

Exclusion criteria: 1. Patients with preoperative blood pressure > 160 / 100mmhg or < 80 / 60mmhg; 2. Patients with heart rate less than 50 beats / min indicated by ECG before operation; 3. Patients with acute respiratory tract inflammation within 2 weeks and without cure history; 4. Patients with severe metabolic diseases such as heart, brain, lung, liver, kidney and diabetes mellitus had previous myocardial infarction, severe myocardial ischemia and severe atrioventricular block; 5. Predict the patients who may or have had difficult airway or have a history of abnormal anesthesia recovery; 6. Patients with obvious electrolyte disorder such as hyperkalemia; 7. Patients with long-term use of immunosuppressants such as hormones or with a history of adrenocortical depression; 8. Patients who are known to be allergic to emulsions and opioids; 9. Patients who used other sedative and analgesic drugs before operation (including injection, oral administration and use of relevant Chinese patent medicines); 10. Patients suspected of abusing narcotic analgesics or sedatives; 11. Patients with neuromuscular system diseases and mental diseases who can not cooperate and cannot communicate.

Design outcomes

Primary

MeasureTime frame
Sedation hypotension incidence;the incidence of hypotension which need to be deal with during sedation;Incidence of hypoxemia;Incidence of apnea;

Secondary

MeasureTime frame
Incidence of specific adverse events;steward sobriety score;Comfort score;Score of disorientation;Awake Score;Score of satisfaction;

Countries

China

Contacts

Public ContactWei Xinchuan

Sichuan Academy of Medical Sciences. Sichuan Provincial People's Hospital

390626473@qq.com+86 18980601553

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026